Immatics Reports Strong Phase 1b Results for Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma
Immatics NV has reported promising results from a Phase 1b trial of anzu-cel, a PRAME-targeted cell therapy for metastatic uveal melanoma. The therapy achieved a confirmed overall response rate of 67% and a median duration of response of 11 months. With a median follow-up of 14.3 months, median overall survival was not reached. Anzu-cel showed favorable tolerability and anti-tumor activity in various metastases. Following these results, Immatics has initiated a Phase 2 cohort for further evaluation.
Immatics NV has announced updated data from a Phase 1b clinical trial evaluating anzu-cel (anzutresgene autoleucel, IMA203), a PRAME-targeted cell therapy, in patients with metastatic uveal melanoma. The data, presented at the European Society for Medical Oncology (ESMO) Congress 2025 during the Presidential Symposium III, included results from 16 patients who received a one-time infusion of anzu-cel. The therapy demonstrated a confirmed overall response rate (cORR) of 67%, a median duration of response (mDOR) of 11.0 months, and a median progression-free survival (mPFS) of 8.5 months. Median overall survival was not reached at a median follow-up of 14.3 months. Anzu-cel was reported to have a favorable tolerability profile and showed anti-tumor activity across various metastases, including liver lesions, and in patients previously treated with TCR-based therapies. Based on these results and the high prevalence of PRAME in uveal melanoma, Immatics has initiated a Phase 2 cohort in patients with metastatic uveal melanoma. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001134018-en) on October 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
